Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
MeiraGTx Holdings PLC
MGTXView Detailed Chart
6.540USD
+0.049+0.77%
Market hours （ET）Quotes delayed by 15 min
512.72MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.77%
5 Days
0.00%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
5
analysts
BUY
Current Rating
23.600
Target Price
276.40%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
556
Total
5
Median
6
Average
Company name
Ratings
Analysts
MeiraGTx Holdings PLC
MGTX
5
CRISPR Therapeutics AG
CRSP
29
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Moderna Inc
MRNA
27
1
2
3
...
111
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
News
More news coming soon, stay tuned...
Company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Company codeMGTX
CompanyMeiraGTx Holdings PLC
CEODr. Alexandria Forbes, Ph.D.
Websitehttps://meiragtx.com/
